Ηλεκτρονικά η εξυπηρέτηση των πολιτών από τη Λιμενική Αστυνομία (e-ΔΛΑ)

21 Οκτωβρίου 2020, 17:32
-
Νέα εποχή ξεκινά στις σχέσεις των πολιτών με το λιμενικό Σώμα, με την έναρξη λειτουργίας,…

Σε Χανιά, Ρέθυμνο και Ηράκλειο ο ΥΝΑΝΠ, Γιάννης Πλακιωτάκης, για το Μεταφορικό Ισοδύναμο

21 Οκτωβρίου 2020, 17:23
-
Τα Χανιά, το Ρέθυμνο και το Ηράκλειο θα επισκεφθεί την Πέμπτη 22 και την Παρασκευή…

DARAG announces the sale of non-legacy Italian business to NOBIS

21 Οκτωβρίου 2020, 14:51
-
DARAG Group (“DARAG” or “the Group”), a leading legacy acquirer, announced that it has reached…

Metlife declares fourth quarter 2020 common stock dividend

21 Οκτωβρίου 2020, 14:47
-
MetLife, Inc. (NYSE: MET) announced that its Board of Directors has declared a fourth quarter…

AIG to Report Third Quarter 2020 Results on November 5, 2020 and Host Conference Call on November 6

21 Οκτωβρίου 2020, 14:26
-
American International Group, Inc. (NYSE: AIG) will report financial results for the third quarter ended September 30,…

Munich Re's Supervisory Board appoints Stefan Golling to the Board of Management

21 Οκτωβρίου 2020, 14:17
-
The Supervisory Board of Munich Reinsurance Company has appointed Stefan Golling (44) to the Munich…

Συνολικά 24 κατηγορίες εισοδημάτων απαλλάσσονται από την ειδική εισφορά αλληλεγγύης

21 Οκτωβρίου 2020, 14:13
-
Την κατάργηση της εισφοράς αλληλεγγύης για τους μισθούς που θα λάβουν χιλιάδες εργαζόμενοι το 2021…

Munich Re posts quarterly result of approx. €200m

21 Οκτωβρίου 2020, 14:11
-
In the third quarter, Munich Re registered COVID-19-related losses totalling about €800m in reinsurance. The…

Σε νέες εγκαταστάσεις στο Μαρούσι τα γραφεία της YAMAHA

21 Οκτωβρίου 2020, 13:59
-
Σε νέες, υπερσύγχρονες εγκαταστάσεις στο Μαρούσι βρίσκονται πλέον τα γραφεία της YAMAHA, μαζί και με…

Στο Λονδίνο σήμερα ο Νότης Μηταράκης

21 Οκτωβρίου 2020, 13:54
-
Στο Λονδίνο μεταβαίνει σήμερα ο υπουργός Μετανάστευσης και Ασύλου, Νότης Μηταράκης, όπου και θα συναντηθεί…

Κέρδη 236% μετά από φόρους στο εννεάμηνο για την «Παπουτσάνης»

21 Οκτωβρίου 2020, 13:46
-
Σημαντική ανάπτυξη του κύκλου εργασιών και αύξηση των κερδών ανακοίνωσε η Παπουτσάνης ΑΒΕΕ για το…

ΤτΕ: Σε ελεύθερη πτώση τα έσοδα του τουρισμού στο 8μηνο

21 Οκτωβρίου 2020, 13:33
-
Μόλις 2,68 δισ. ευρώ ήταν τα τουριστικά έσοδα τους πρώτους οκτώ μήνες του έτους, έναντι…

Revoil: Έκδοση ομολόγου ύψους 1 εκατ. ευρώ

21 Οκτωβρίου 2020, 13:24
-
Η Εταιρεία Revoil Α.Ε.Ε.Π. ανακοινώνει ότι, σε εκτέλεση της από 15/10/2020 απόφασης του Διοικητικού της…

Πέθανε από κορωνοϊό ο Γρεβενιώτης μουσικός Ζήσης Κασιάρας

21 Οκτωβρίου 2020, 13:17
-
Έφυγε τελικά από τη ζωή, σε ηλικία 53 ετών, ο βιρτουόζος του βιολιού και συνεργάτης…

Germany: EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment

  • European Investment Bank and Atriva Therapeutics sign financing agreement of €24 million for the research, development and clinical testing of the company’s lead product candidate against influenza and COVID-19
  • Atriva’s ATR-002 molecule is the only host-cell targeting antiviral therapeutic specifically developed to treat severe respiratory infections caused by RNA (ribonucleic acid) viruses – it may prevent progression to critical-stage COVID-19 in hospitalised patients and holds strong potential in the current pandemic
  • The EIB venture debt transaction is financed under the Infectious Diseases Finance Facility set up as part of Horizon 2020, the EU research and innovation programme for 2014-2020

The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses. RNA viruses cause diseases such as influenza, SARS and COVID-19. Atriva’s ATR-002, an oral small molecule, has been proven to block the viral propagation of SARS-CoV-2 in pre-clinical trials, making it a much-needed therapeutic option for patients with moderate to severe COVID-19 symptoms who require hospitalisation.

“While one needs to be careful when comparing COVID-19 to the flu, it might be helpful that both diseases have overlaps in their mechanisms of infection,” said Ambroise Fayolle, EIB Vice-President in charge of innovation and transactions in Germany. “If, as Atriva’s research indicates, one small molecule can work to treat both diseases, this would be excellent news not only for the millions of people who fall ill from the flu every year but also for the many more who are affected by the coronavirus lately. An effective treatment would also lift a huge burden from our health systems and help mitigate the impact these diseases have on our daily lives and the economy. This is a case where EIB financing can contribute to addressing an extremely high unmet medical need, which is something I am proud of.”

Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth, said: “The European Union is doing all in its power to protect Europeans against coronavirus. The European Commission is coordinating the Coronavirus Global Response, the global action for universal access to tests, treatments and vaccines against coronavirus and for the global recovery. With this loan to Atriva, the EU continues its support for the development of innovative Covid-19 treatments. Their therapy can add to the range of complementary solutions that we need to tackle this disease.”

Dr Rainer Lichtenberger, co-founder and CEO of Atriva, said: “The EIB clearly understands the need for an effective antiviral therapy against influenza and COVID-19 and the potential such a treatment holds to help patients around the world. We are grateful for the EIB’s support in advancing the clinical development of ATR-002 as an innovative host-targeting therapy against these prevalent and potentially devastating diseases. With the funding from the EIB, we can now take the next development steps –starting a Phase II study in patients with moderate to severe COVID-19 infections, followed by further clinical development work in influenza.” He continued: “When the coronavirus pandemic hit us all earlier this year, we saw that Atriva’s technology had the potential to play an important role in the fight against COVID-19, and we are excited to move forward in this work now. Our ultimate goal, though, is to develop a broad-spectrum antiviral drug that will also be effective against future viral outbreaks.”

ATR-002 has been developed specifically to treat respiratory viral infections by inhibiting MEK, a host cell factor required for the replication of various RNA viruses, including the influenza virus and SARS-CoV-2. Atriva’s pre-clinical studies, performed at the Universities of Tübingen and Münster, have demonstrated that MEK inhibition by ATR-002 also prevents SARS-CoV-2 replication.

In addition to its antiviral efficacy, ATR-002 shows a second beneficial effect: the MEK-inhibitor was able to significantly decrease pro-inflammatory cytokine and chemokine expression in cells. Cytokines and chemokines are proteins that coordinate the immune response throughout the body. In patients with COVID-19, ATR-002 could prevent a cytokine storm and the associated disease progression to a life-threatening condition.

This dual benefit, antiviral activity and immunomodulation, positions ATR-002 as a promising therapeutic candidate. Atriva has filed the respective patents with the European Patent Office. In addition, ATR-002 successfully completed a Phase I clinical trial in 2019 where it demonstrated excellent safety and tolerability in healthy volunteers.

Atriva will receive the EIB loan in three tranches upon the completion of pre-defined milestones. The funds will support the company’s R&D for ATR-002, including clinical trial expenses, the technical transfer and manufacturing ramp-up needed to reach a commercial scale, as well as regulatory, intellectual property, pharmacovigilance and market access activities. Atriva will now start a multinational, double-blind, randomised clinical Phase II study in hospitalised patients with moderate to severe COVID-19 infections.

The loan is backed by the Infectious Diseases Finance Facility (IDFF) set up as part of the EU’s Horizon 2020 programme. The IDFF is an example of successful collaboration between the European Commission and the EIB in the face of a health crisis. Through this facility, the EIB has supported European companies with total lending of around €400 million for developing cures, vaccines and diagnostics for various infectious diseases, most prominently the coronavirus.

Τρίτο κρούσμα κορωνοϊού στη Βουλή - Αυστηρότερα μέτρα από σήμερα

21 Οκτωβρίου 2020, 13:01
-
Νέα αυστηρότερα μέτρα θα ισχύσουν από σήμερα Τετάρτη 21 Οκτωβρίου στη Βουλή, μετά το τρίτο…

Spain: EIB Group and Santander provide over €900 million to support SMEs affected by the COVID-19 crisis

21 Οκτωβρίου 2020, 12:52
-
The EIB Group is subscribing a total of €198 million of the securitisation issued by Santander…

V.Group and Costamare Shipping Company S.A. expand existing strategic partnership

21 Οκτωβρίου 2020, 12:47
-
Global ship management and marine support services provider V.Group and Costamare Shipping Company S.A. (“Costamare”)…

Videos

  • 19th Hydra Meeting 2017 - 9
    • 19th Hydra Meeting 2017 - 9

    • Watch Video

  • 19th Hydra Meeting 2017 - 6
    • 19th Hydra Meeting 2017 - 6

    • Watch Video

  • 19th Hydra Meeting 2017 - 4
    • 19th Hydra Meeting 2017 - 4

    • Watch Video

  • 19th Hydra Meeting 2017 - 2
    • 19th Hydra Meeting 2017 - 2

    • Watch Video